Cornell researchers have developed a new vaccine platform that could provide more robust, longer-lasting protection from both ...

What is a viral vector? Viral vector vaccines use a version of a mild virus to safely deliver instructions in the form of genetic code to our body cells. These instructions enable your body to produce ...

How it works Convidencia is a viral vector vaccine using adenovirus five. With a viral vector, there is essentially a viral particle, which is programmed not to replicate. So, what is administered ...

Alignment with National Health Security Goals: GeoVax’s focus on U.S.-based vaccine production supports HHS’s priority of reducing dependency on foreign pharmaceutical supply chains, ensuring ...

The proof-of-concept study is one of the first to combine B and T cell analysis and potentially paves the way for tests that ...

Department of Health and Human Services Secretary Robert F. Kennedy Jr. paused a $240 million contract to create a new coronavirus vaccine.

The global viral vector and plasmid DNA manufacturing market size is calculated at USD 8.66 billion in 2025 and is expected ...

The other COVID-19 vaccines authorised for use in the EU are mRNA vaccines (Pfizer/BioNTech and Moderna) or viral vector vaccines (AstraZeneca and Janssen).

Recent Studies Support Diversified Vaccine Strategies, Aligning with GeoVax's MVA-Based GEO-CM04S1 for Enhanced Protection, ...

Despite decades of efforts, tuberculosis remains a global health crisis, claiming over 1.3 million lives annually. In a comprehensive review published in Molecular Biomedicine , an international team ...

The Global Viral Vector Market was valued at approximately USD 3.10 billion in 2022 and is projected to grow at a robust CAGR of more than 11.5% during the forecast period 2023-2030. Read the Market ...

As the industry moves towards a more integrated and diversified vaccine ecosystem, GeoVax’s MVA-based vaccines should provide a scalable, durable, and globally accessible solution that enhances the ...